

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Information Disclosure
Statement



DOCKET NO.: D5716CIP2
SERIAL NO.: 08/631,470
APPLICANT: Staley A. Brod
FILING DATE: 4/15/96
GROUP:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
---------------------	--------------------	------	------	-------	----------	----------------

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Publication: Patent Cooperation Treaty (PCT)

Translation: English

Document Number: _____ **Date:** _____

Country: Great Britain

Class Or Subclass

Patent: Yes ☐ No ☐

Title:

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

- 12 a. E. C. Butcher. *The Regulation of Lymphocyte Traffic*. Current Topics in Microbiology and Immunology, Vol. 128, pp. 85-122 (1986).
- 12 b. L. Paulesu, et al. Oral Administration of Human ?Recombinant Interferon-a2 in Rats. Elsevier Science Publishers B.V. (Biomedical Division), 46, pp. 199-202 (1988).
- 12 c. Velio Bocci. Absorption of Cytokines via Oropharyngeal-Associated Lymphoid Tissues. Clin. Pharmacokinet. 21 (6), pp. 411-117 (1991).
- 12 d. K. Cantell and Liisa Pyhala. Circulating Interferon in Rabbits after Administration of Human Interferon by Different Routes. Virol. 20, pp. 97-104 (1973).
- 12 e. D. Goldstein, et al. Human Biologic Response Modification by Interferon in the Absence of Measurable Serum Concentrations: A Comparative Trial of Subcutaneous and Intravenous Interferon-β serine. Journal of the National Cancer Institute, Vol. 81, No. 14, pp. 1061-1068 July 19, (1989).
- 12 f. Elaine Radwanski, Ph.D, et al. Pharmacokinetics of Interferon α-2b in Healthy Volunteers. J. Clin. Pharmacol, 27, pp. 432--435 (1987).
- 12 g. Robert J. Wills, et al. Pharmacokinetics of Recombinant Alpha A Interferon Following IV Infusion and Bolus, IM, and PO Administration to African Green Monkeys. Journal of Interferon Research, Vol. 4, 3, pp. 399-409 (1984).
- 12 h. D. M. Gibson, et al. Pharmacokinetics of Recombinant Leukocyte A Interferon Following Various Routes and Modes of Administration to the Dog. Journal of Interferon Research, vol. 5, pp. 403-408 (1985).
- 12 i. Anne P. Larocca, et al. Evaluation of Neutralizing Antibodies in Patients Treated with Recombinant Interferon-β ser. Journal of Interferon Research, Vol 9, Suppl. 1, pp. S51-S60 (1989).

62 j. P. L. Witt, et al. Absence of Biological Effects of Orally Administered Interferon- β ser. Journal of Interferon Research, Vol. 12, pp. 411-413 (1992).

62 k. W. Robert Fleischmann, Jr., et al. Orally Administered Interferons Exert Their White Blood Cell Suppressive Effects via a Novel Mechanism. N urology 13, April (1993)

62 l. Velio Bocci. Immunomodulators as Local Hormones: New Insights Regarding Their Clinical Utilization. Journal of Biological Response Modifiers, 4, pp. 340-352 (1985).

62 m. Michel A. Horisberger. MX PROTEIN: FUNCTION AND MECHANISM OF ACTION. Biotechnology, Ciba-Geigy Ltd., CH-4002 Basel, Switzerland. 1992

Examiner

Sayala

Date Considered

11/6/97

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)